Wall Street ends near flat after recent highs; healthcare climbs

Core US retail sales rise 0.5% in April; Dow down 0.2%, S&P flat, Nasdaq up 0.1%
Comment E-mail Print Share
First Published: Mon, May 13 2013. 10 25 PM IST
Traders work on the floor of the New York Stock Exchange. Photo: AFP
Traders work on the floor of the New York Stock Exchange. Photo: AFP
Updated: Tue, May 14 2013. 08 50 AM IST
New York: US stocks closed little changed on Monday, pausing after hitting record highs last week, but strength in healthcare issues helped to keep declines in check.
The S&P 500 healthcare sector climbed 0.7% and was the day’s best performer.
Shares of Theravance Inc. jumped 17.9% to $41.20 after Irish drugmaker Elan Corp. agreed to a $1 billion deal to buy 21% of the royalties that Theravance receives from GlaxoSmithKline Plc. for its respiratory drugs.
The day’s flat close followed a third straight week of gains on the major indexes, with both the Dow and S&P 500 setting record closing highs last week. The S&P 500 remains up 14.5% for the year so far.
While some analysts argue the long-term trend is still higher, many see momentum waning in the near term in the absence of positive catalysts. Volume has been lighter than average, and volatility has been low in recent days.
“Intraday volatility has essentially been nonexistent. I think it means people are really sitting on the sidelines right now seeing which way it’s going to go,” said Uri Landesman, president of Platinum Partners in New York. He expects the rally to top out in the next two weeks.
The CBOE Volatility index ended down 0.3%.
The Dow Jones industrial average ended down 26.81 points, or 0.18%, at 15,091.68. The Standard & Poor’s 500 Index was up 0.07 point at 1,633.77. The Nasdaq Composite Index was up 2.21 points, or 0.06%, at 3,438.79.
Among the day’s declining issues, Yum Brands Inc. fell 2% to $68.92. After the market closed on Friday, the fast food chain operator posted a steep decline in Chinese April sales.
Other big healthcare group gainers included Pfizer Inc., up 2.3% at $29.37; Gilead Sciences, Inc., up 3.1% at $54.47; and Biogen Idec, up 4.5% at $222.74.
Helping to limit the market’s decline, retail sales rose 0.1% in April, better than the 0.3% drop that had been expected and returning to growth following a decline in March. Excluding autos, gasoline and building materials, core sales rose 0.5%. Retail sales account for about 30% of US consumer spending.
Investors are at odds over whether positive economic data can help the market rise further, or whether it will spell the end of the Federal Reserve’s monetary stimulus, which could derail the rally, said Joseph Tanious, global market strategist at J.P. Morgan Funds.
Other data showed business inventories were unchanged in March for a second straight month, versus expectations of a 0.3% rise, suggesting restocking could help second-quarter economic growth.
Earnings have been mostly better than expected. With 90% of the S&P 500 having reported, 67.2% of companies have topped earnings expectations, according to Thomson Reuters data, even with the average over the past four quarters. Only 46.9% have beaten revenue expectations, below the 52% average over the past four quarters.
US-listed shares of Perion Network surged 10.6% to $13.94 after the Israeli consumer Internet company posted first-quarter earnings.
Volume was roughly 5.3 billion shares traded on the New York Stock Exchange, the Nasdaq and the NYSE MKT, well below the average daily closing volume of about 6.4 billion this year.
Declines outpaced advances on the NYSE by nearly 3 to 2 and the Nasdaq by a ratio of about 13 to 11.
Comment E-mail Print Share
First Published: Mon, May 13 2013. 10 25 PM IST
More Topics: Global markets | Dollar | oil | gold | Dow Jones |
blog comments powered by Disqus
  • Wed, Oct 22 2014. 09 49 PM
  • Wed, Oct 15 2014. 11 40 PM
Subscribe |  Contact Us  |  mint Code  |  Privacy policy  |  Terms of Use  |  Advertising  |  Mint Apps  |  About HT Media  |  Jobs
Contact Us
Copyright © 2014 HT Media All Rights Reserved